

Date: <i>DD-MMM-YYYY</i>	05-Nov-2020
To: <i>Name, Address, and Company</i>	Carlota Vinals Head Regulatory Affairs Infectious Diseases Moderna, Inc. 200 Technology Square Cambridge, MA 02139
Subject: <i>Brief description of the letter content</i>	Right of Reference Letter Emergency Use Authorization EUA200124 VIRACOR Assay: SARS-CoV-2 RT-qPCR Swab in saline

Dear Ms. Vinals,

VIRACOR Eurofins hereby grants a right of reference to Moderna, Inc. for EUA200124 for the Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 test (Molecular LDT COVID-19 Authorized Test). This letter permits Moderna, Inc. to reference the performance data in VIRACOR's EUA200124 for their SARS-CoV-2 vaccine candidate (mRNA-1273) under IND19745. In case you should have any questions regarding this letter or need additional information from us, please contact me by email at (b) (6) @viracor-eurofins.com or by phone at (b) (6)

Sincerely,

(b) (6)

Eurofins Viracor BioPharma Services, Inc.


Letter for Right to Reference EUA COVID Assay

Final Audit Report

2020-11-05

Created:	2020-11-05
By:	(b) (6) @viracor-eurofins.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAXcobkM2FoUugTh5nBhjl8UpdlfyQH8Pf


"Letter for Right to Reference EUA COVID Assay" History

 Document created by (b) (6) @viracor-eurofins.com)

2020-11-05 - 10:26:52 PM GMT- IP address (b) (6)

 (b) (6) @viracor-eurofins.com) verified identity with Adobe Sign authentication

2020-11-05 - 10:27:46 PM GMT

 Document e-signed by (b) (6) @viracor-eurofins.com)

Signature Date: 2020-11-05 - 10:27:46 PM GMT - Time Source: server- IP address: (b) (6)

 Agreement completed.

2020-11-05 - 10:27:46 PM GMT